ArticleJHEP reports : innovation in hepatology2026
Plasma IGFBP7 improves risk reclassification for liver-related outcomes: Insights from proteo-transcriptomic profiling.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2026Review
- The role of healthy lifestyle in the association between hepatic fibro-inflammation and steatosis and brain aging-a cross-sectional study.Frontiers in aging neuroscience · 2026Article
- Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Advanced liver fibrosis is a pivotal predictor of liver-related outcomes (LROs), yet existing non-invasive tests offer limited prognostic accuracy. We aimed to identify novel plasma protein biomarkers that enhance long-term risk stratification for LROs. Methods: Proteomic analyses were first conducted in 191 patients with metabolic dysfunction-associated steatotic liver disease (MASLD), including 79 with advanced fibrosis and 112 with mild fibrosis, to identify differential plasma proteins. These proteomic findings were then integrated with liver transcriptional profiling from 206 patients with MASLD, comprising 68 with advanced fibrosis and 138 with mild fibrosis, to determine candidate biomarkers. The prognostic utility of these biomarkers was validated in 42,979 participants from the UK Biobank with a median follow-up of 13 years. Discriminatory performance and cumulative incidence were assessed using competing-risk methodologies. Results: Proteo-transcriptomic integration identified 123 concordant candidates, among which four plasma proteins (ADAMTSL2, IGFBP7, MFAP4, and CLSTN2) demonstrated robust diagnostic performance for advanced fibrosis (AUCs 0.821-0.889). In the UK Biobank cohort, IGFBP7 emerged as the strongest predictor of LROs, outperforming Fibrosis-4, AST to Platelet Ratio Index, and Chronic Liver Disease Conclusions: Plasma IGFBP7 is a robust and independent predictor of liver-related outcomes and significantly enhances risk stratification beyond conventional clinical tools. Impact and implications: This study demonstrates that IGFBP7 is both a biomarker of advanced liver fibrosis and a strong long-term predictor of liver-related outcomes. The integration of IGFBP7 with conventional non-invasive tests enhances the refinement of risk prediction. Among individuals with low CLivD scores, those with high IGFBP7 levels had a substantially increased incidence of liver-related outcomes (2.5%), while low IGFBP7 levels were associated with favorable outcomes even in high CLivD groups (0.8%). This enables more precise identification of patients who may benefit from early referral
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.